AbCellera Biologics Inc (NAS:ABCL)
$ 2.995 0.045 (1.53%) Market Cap: 871.33 Mil Enterprise Value: 299.59 Mil PE Ratio: 0 PB Ratio: 0.81 GF Score: 66/100

Abcellera Biologics Inc at Goldman Sachs Healthcare Conference Transcript

Jun 13, 2023 / 08:20PM GMT
Release Date Price: $7.47 (+0.95%)
Andrea R. Tan
Goldman Sachs Group, Inc., Research Division - Research Analyst

Perfect. Well, thank you, everyone, for joining us this afternoon to speak with AbCellera, CEO, Carl Hansen. Thank you so much for joining us.

Carl L.G. Hansen
AbCellera Biologics Inc. - CEO, President & Chairperson

Thanks, Andrea. Great to be here.

Questions & Answers

Andrea R. Tan
Goldman Sachs Group, Inc., Research Division - Research Analyst

So maybe to start, AbCellera, a company that's positioned at the intersection of biotech and tech, which is hot right now. But maybe for some of -- some of the people in the crowd who may be less familiar with your company, maybe describe your business thesis here and how that really helps fit you into the drug discovery and development process.

Carl L.G. Hansen
AbCellera Biologics Inc. - CEO, President & Chairperson

Great. Sure, happy to. So AbCellera was founded a little over 10 years ago. And the business thesis was essentially

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot